Download
1 / 19
210 likes | 615 Views
2. . . Boston Scientific Innovation: Internal
E N D
1. Boston Scientific Pipeline Update Boston Scientific New Product Development
Terry Vick, PhD Note to Boston Scientific Presenter:
You may not make any inferences or claims about the safety, efficacy or availability of unapproved devices shown in this presentation. This presentation may be shown to current and potential customers. Distribution of this presentation (in any format) is expressly forbidden. The information in this deck must be presented in conjunction with the appropriate dialogue / talk track, and we do not want this information to fall into the hands of the competitors.
Please see accompanying notes for additional detail.
There are some risks from giving this presentation:
DO NOT leave presentation behind
Carefully read the note to the presenter and on title slide; devices discussed are NOT yet approved for use; we cannot make inferences or claims about the safety, efficacy, or availability of the products discussed
You will not see dates in this presentation; some products are in final development stages, but there is still risk in final testing results & regulatory approvals with these products
The slides present proposed device intent and design goals for each product, not exactly what each device will do or any key proven benefits; it is too early to make claims or to set expectations with these products
To the presenter:
The purpose of this slide deck is:
to provide a tool to give customers confidence in Boston Scientific’s commitment to R&D innovation
To give customers idea of what to expect from BSC in coming years
What this slide deck is NOT:
this is NOT an all inclusive look at what is in development at Boston Scientific; it includes some of the most common questions when New Product Management meets with customers
Not meant to answer every question but to support the CRV talk track
Note to Boston Scientific Presenter:
You may not make any inferences or claims about the safety, efficacy or availability of unapproved devices shown in this presentation. This presentation may be shown to current and potential customers. Distribution of this presentation (in any format) is expressly forbidden. The information in this deck must be presented in conjunction with the appropriate dialogue / talk track, and we do not want this information to fall into the hands of the competitors.
Please see accompanying notes for additional detail.
There are some risks from giving this presentation:
DO NOT leave presentation behind
Carefully read the note to the presenter and on title slide; devices discussed are NOT yet approved for use; we cannot make inferences or claims about the safety, efficacy, or availability of the products discussed
You will not see dates in this presentation; some products are in final development stages, but there is still risk in final testing results & regulatory approvals with these products
The slides present proposed device intent and design goals for each product, not exactly what each device will do or any key proven benefits; it is too early to make claims or to set expectations with these products
To the presenter:
The purpose of this slide deck is:
to provide a tool to give customers confidence in Boston Scientific’s commitment to R&D innovation
To give customers idea of what to expect from BSC in coming years
What this slide deck is NOT:
this is NOT an all inclusive look at what is in development at Boston Scientific; it includes some of the most common questions when New Product Management meets with customers
Not meant to answer every question but to support the CRV talk track
2. 2 Boston Scientific Innovation: Internal & External Investment in New Technology
3. Boston Scientific’s Priority Growth Initiatives
4. Focus on BSC Technology & Acquisitions in Interventional Cardiology
5. Market Demands for Future Generations of Drug Eluting Stents
7. Relative Drug Coating Weights Across Various DES Platforms
8. Thin Stent Strut Profiles on New Stent Platforms
10. 10 New Cardiovascular Technologies: Left Atrial Appendage (LAA) Occlusion
11. Priority Growth Initiatives Atritech, Inc. – Acquired March 2011
12. The WATCHMANTM Left Atrial Appendage Closure 12
13. PROTECT-AF Clinical Trial Results Prospective, 2:1 randomized study of WATCHMANTM LAA Device vs. Long-term Warfarin Therapy (n=800)
14. 14 New Cardiovascular Technologies: Percutaneous Aortic Valve
15. Priority Growth Initiatives Sadra Medical – Acquired January 2011
16. The Lotus™ Valve System
18. Priority Growth Initiatives Hypertension
20. 20
